Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 6/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17631632 | 1.00 | MAPK8 (0.52) | MAPK8MAPK10MAPK14USP30ACVRL1 | |
| SCHEMBL17643827 | 0.84 | PTPN2 (0.53) | MAPK8MAPK10MAPK14USP30ABL1 | |
| SCHEMBL28493108 | 0.84 | PTPN2 (0.53) | MAPK8MAPK10MAPK14USP30ABL1 | |
| SCHEMBL29676896 | 0.83 | PIK3C3 (0.56) | MAPK8MAPK10ACVRL1ABL1PIK3C3 | |
| SCHEMBL18170428 | 0.83 | PIK3C3 (0.56) | MAPK8MAPK10ACVRL1ABL1PIK3C3 | |
| SCHEMBL17631575 | 0.83 | ABL1 (0.65) | ABL1GSK3B | |
| SCHEMBL17631573 | 0.83 | ABL1 (0.65) | ABL1GSK3B | |
| SCHEMBL15542212 | 0.83 | ABL1 (0.62) | ACVRL1ABL1PIK3C3GSK3B | |
| SCHEMBL18640001 | 0.82 | ABL1 (0.55) | ACVRL1ABL1PIK3C3GSK3BLMNA | |
| SCHEMBL23893005 | 0.80 | ABL1 (0.56) | ACVRL1ABL1PIK3C3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| CN-111592534-A | Novel compounds | 特殊治疗有限公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3197883-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| US-20190330202-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| EP-3197883-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774078-B2 | Compounds | UCHL1, UCHL3, UCHL5 | MAPK8 3336/4885MAPK10 2216/4885MAPK14 3850/4885 |
| US-20180162852-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | MAPK8 3509/4885MAPK10 2204/4885MAPK14 4014/4885 |
| US-10392380-B2 | Compounds | UCHL1, UCHL3, UCHL5 | MAPK8 3336/4885MAPK10 2216/4885MAPK14 3850/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | MAPK8 3336/4885MAPK10 2216/4885MAPK14 3850/4885 |
| US-20200369658-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | MAPK8 3509/4885MAPK10 2204/4885MAPK14 4014/4885 |
| US-20190330202-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | MAPK8 3509/4885MAPK10 2204/4885MAPK14 4014/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | MAPK8 3509/4885MAPK10 2204/4885MAPK14 4014/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | MAPK8 3509/4885MAPK10 2204/4885MAPK14 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.